You searched for Humanized antibody - Page 5 of 45

In Depth 18 Sep 2024

Two targets, one solution: The rise of bispecific antibodies

…to manufacture only one molecule and patients may need only one antibody treatment. This is beneficial because it lessens the patient burden and also overcomes the potential issues surrounding the…

September 18, 2024 - 9 minutesmins - By Willow Shah-Neville

News and Trends 29 Aug 2019

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

…also fuel the expansion of HiFiBiO’s antibody production technology, which is based on screening hundreds of single immune cells at a time for the most effective antibody drug candidate. HiFiBiO…

August 29, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Oct 2022

Oxford BioTherapeutics enters into antibody agreement with Genmab

…conjugate (ADC) based therapies designed to fulfill major unmet patient needs in cancer therapeutics. These include bispecific, chimeric antigen receptor T-cell (CAR-T), Antibody Drug Conjugate (ADC) and Antibody Dependent Cell-mediated…

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

United BioPharma gets FDA approval for phase 2 HIV drug trial

…multi-drug resistance (MDR). The study protocol is entitled: “A Single arm Open Label Phase 2 trial of anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with…

August 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 30 May 2023

Potential targets against natural killer/T-cell lymphoma found

…greatly needed. We can use different strategies to target these. Proteolysis-targeting chimera (PROTAC) targeting TOX2 to degrade TOX2 protein may be a viable NKTL therapy option. A humanized antibody, PRL3-zumab,…

May 30, 2023 - 3 minutesmins - By Jim Cornall

More News! 8 Feb 2017

The First Stroke Drug in Decades? French Biotech gets closer to the Clinic

…Medicine & Healthcare products Regulatory Agency (MHRA) received in January. Acticor’s candidate, ACT017, is a humanized antibody fragment (Fab) that inhibits the activity of platelet glycoprotein VI (GPVI). This strategy…

February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Nov 2022

Lipum starts chronic inflammatory disease drug study

…have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major unmet medical need in the…

November 8, 2022 - 2 minutesmins - By Jim Cornall

In Depth 27 Apr 2017

Spain: An Emerging Star in the European Biotech Community

…has been a great opportunity for Versant Ventures and Canadian Northern Biologicals. Mosaic and Northern merged late last year to propel Mosaic’s humanized antibody into clinical trials for oncology this…

April 27, 2017 - 6 minutesmins - By External Contributor

News and Trends 6 Sep 2017

What to Do When the Microorganisms Get to You

…thrombus formation without disrupting natural hemostasis. ACT017 is a humanized antibody fragment which inhibits the platelet glycoprotein VI that plays a role in thrombus growth. Phase I clinical trials are…

September 6, 2017 - 5 minutesmins - By External Contributor

Best in Biotech 29 Feb 2024

6 biotech companies making a difference in pediatric care

…announced the signing of an exclusive license agreement with St. Jude Children’s Research Hospital for its lead candidate Hu14.18, a humanized antibody in development by St. Jude for the treatment…

February 29, 2024 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 23 May 2025

Finland: Pushing biotech forward in the land of a thousand lakes

…results Faron Pharmaceuticals, based in Turku, Finland, is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and other diseases. The company’s lead product, bexmarilimab, is a humanized antibody that targets…

May 23, 2025 - 10 minutesmins - By Jules Adam

News and Trends 6 Sep 2017

Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment

Tiziana makes moves towards a €37B market with an oral monoclonal antibody (mAb) formulation to treat non-alcoholic steatohepatitis (NASH) . Tiziana, which has previously developed compounds targeting the second most…

September 6, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Humanized antibody

Two targets, one solution: The rise of bispecific antibodies

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

Oxford BioTherapeutics enters into antibody agreement with Genmab

United BioPharma gets FDA approval for phase 2 HIV drug trial

Potential targets against natural killer/T-cell lymphoma found

The First Stroke Drug in Decades? French Biotech gets closer to the Clinic

Lipum starts chronic inflammatory disease drug study

Spain: An Emerging Star in the European Biotech Community

What to Do When the Microorganisms Get to You

6 biotech companies making a difference in pediatric care

Finland: Pushing biotech forward in the land of a thousand lakes

Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!